Free Trial
OTCMKTS:INTI

Inhibitor Therapeutics (INTI) Stock Price, News & Analysis

Inhibitor Therapeutics logo
$0.05 0.00 (-2.09%)
As of 06/27/2025 03:16 PM Eastern

About Inhibitor Therapeutics Stock (OTCMKTS:INTI)

Key Stats

Today's Range
$0.04
$0.05
50-Day Range
$0.04
$0.06
52-Week Range
$0.03
$0.10
Volume
4,000 shs
Average Volume
6,353 shs
Market Capitalization
$8.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.

Receive INTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibitor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INTI Stock News Headlines

INTI Inhibitor Therapeutics, Inc.
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new invention… This could send many popular AI stocks crashing, including Nvidia. And it could happen starting as soon as June 1st.
Indaptus Therapeutics initiates Phase 1 study of Decoy20
See More Headlines

INTI Stock Analysis - Frequently Asked Questions

Inhibitor Therapeutics' stock was trading at $0.0601 on January 1st, 2025. Since then, INTI shares have decreased by 22.0% and is now trading at $0.0469.
View the best growth stocks for 2025 here
.

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) issued its quarterly earnings data on Friday, March, 28th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Shares of INTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibitor Therapeutics investors own include AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Abacus Health Products (ABAHF), Avino Silver & Gold Mines (ASM), Bank of America (BAC) and BlackBerry (BB).

Company Calendar

Last Earnings
3/28/2025
Today
6/29/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:INTI
Employees
1
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.34 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.01 per share
Price / Book
4.69

Miscellaneous

Free Float
164,636,000
Market Cap
$8.09 million
Optionable
Not Optionable
Beta
-0.53
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (OTCMKTS:INTI) was last updated on 6/29/2025 by MarketBeat.com Staff
From Our Partners